Mutation Sites Are Distant from Remdesivir Binding Site in Human SARS-CoV-2 RNA-Dependent RNA Polymerase

05 January 2021, Version 1
This content is a preprint and has not undergone peer review at the time of posting.


The comparison of 10,929 human SARS-CoV-2 RdRp protein sequences representing six geographical locations with the reference protein sequence in human SARS-CoV-2 genome isolate from Wuhan, China, identified 222 distinct mutation sites in the RdRp protein. The NiRAN and interface domains, Fingers, Palm and Thumb sub-domains were each associated with ~20% or more mutations compared to mutations in N-terminal, beta-hairpin or C-terminal regions of the protein. The Pro4715Leu mutation was predominantly observed in RdRp proteins from all six geographical locations; Africa, Asia, Europe, North America, Oceania and South America. None of the mutation site residues were within 3.2 Å interacting distance from remdesivir as observed in the three-dimensional cryo-electron microscopy structures of RdRp protein complexes available in the Protein Data Bank. Therefore, the mutations in human SARS-CoV-2 RdRp proteins, described in the present work, are not likely to cause resistance to remdesivir binding. Further, the mutations were also not associated with functionally important residues that would affect the enzyme’s function.


human SARS-CoV-2
RNA dependent RNA polymerase (RdRp)
Geographical Locations
mutation mapping
RdRp sequence
RdRp three-dimensional structure

Supplementary weblinks


Comments are not moderated before they are posted, but they can be removed by the site moderators if they are found to be in contravention of our Commenting Policy [opens in a new tab] - please read this policy before you post. Comments should be used for scholarly discussion of the content in question. You can find more information about how to use the commenting feature here [opens in a new tab] .
This site is protected by reCAPTCHA and the Google Privacy Policy [opens in a new tab] and Terms of Service [opens in a new tab] apply.